Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Mathew MacCumber, EURETINA 2019 – Updates from the DCRC Retina Network studies

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 17th 2019

Mathew MacCumber (Rush University Medical Centre, Chicago) provides seom updates from the DCRC Retina Protocls including the findings from Protocol V.

Questions:
1. What have been the most important developments in DME in the last year?
2. What is the current standard of care for patients with centre-involved DME with good vision?
3. Could you tell us a little about the Protocol V trial and its findings?
4. What have been the most interesting findings from the other DRCR Retina Network Protocols ongoing trials?

Disclaimer: The thoughts and opinions expressed in this video are those of Mathew MacCumber and don’t necessarily reflect though of the DRCR Retina Network.

Support: No funding was received in the production of this video.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup